{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:36:47Z","timestamp":1761183407435,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.dmpk.2018.03.001","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T23:33:05Z","timestamp":1520465585000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A phase I, open-label, single-dose micro tracer mass balance study of 14C-labeled ASP7991 in healthy Japanese male subjects using accelerator mass spectrometry"],"prefix":"10.1016","volume":"33","author":[{"given":"Daisuke","family":"Miyatake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitsugu","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Taniuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Katashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiji","family":"Sawamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dmpk.2018.03.001_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0731-7085(00)00397-6","article-title":"A\u00a0validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts","volume":"24","author":"Garner","year":"2000","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"7","key":"10.1016\/j.dmpk.2018.03.001_bib2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1124\/dmd.30.7.823","volume":"30","author":"Garner","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmpk.2018.03.001_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10637-007-9041-z","article-title":"Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry","volume":"25","author":"Beumer","year":"2007","journal-title":"Invest New Drugs"},{"issue":"12","key":"10.1016\/j.dmpk.2018.03.001_bib4","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1124\/dmd.114.059675","article-title":"Disposition and metabolic profiling of [(14)C]cerlapirdine using accelerator mass spectrometry","volume":"42","author":"Tse","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2018.03.001_bib5","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.nimb.2007.02.001","article-title":"Bioanalysis works in the IAA AMS facility: comparison of AMS analytical method with LSC method in human mass balance study","volume":"259","author":"Miyaoka","year":"2007","journal-title":"Nucl Instrum Methods Phys Res Sect B Beam Interact Mater Atoms"},{"issue":"2","key":"10.1016\/j.dmpk.2018.03.001_bib6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2174\/187231211795305249","article-title":"Disposition and mass balance of [14C]vernakalant after single intravenous and oral doses in healthy volunteers","volume":"5","author":"Mao","year":"2011","journal-title":"Drug Metab Lett"},{"issue":"4","key":"10.1016\/j.dmpk.2018.03.001_bib7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.111.043588","article-title":"Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective beta(3)-adrenoceptor agonist, after oral administration to healthy male volunteers","volume":"40","author":"Takusagawa","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmpk.2018.03.001_bib8","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40262-015-0271-5","article-title":"Clinical pharmacokinetic studies of enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.dmpk.2018.03.001_bib9","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3109\/00498254.2015.1026864","article-title":"Human mass balance, metabolite profile and identification of metabolic enzymes of [(1)(4)C]ASP015K, a novel oral janus kinase inhibitor","volume":"45","author":"Oda","year":"2015","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.dmpk.2018.03.001_bib10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00280-016-2999-5","article-title":"Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients","volume":"77","author":"Poondru","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.dmpk.2018.03.001_bib11","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1124\/dmd.111.039339","article-title":"A\u00a0single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry","volume":"39","author":"Graham","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2018.03.001_bib12","unstructured":"Guidance for the performing of microdose clinical trials (PFSB\/ELD notification No. 0603001, dated 3 Jun 2008)."},{"issue":"6","key":"10.1016\/j.dmpk.2018.03.001_bib13","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/clpt.2010.206","article-title":"Microdose study of 14C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of parent drug and metabolites in healthy subjects","volume":"88","author":"Tozuka","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmpk.2018.03.001_bib14","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ejps.2013.05.016","article-title":"Microdose pharmacogenetic study of (1)(4)C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9 *3 on its pharmacokinetics and metabolism","volume":"49","author":"Ikeda","year":"2013","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"10.1016\/j.dmpk.2018.03.001_bib15","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1161\/hy1001.096358","article-title":"Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease","volume":"38","author":"Blacher","year":"2001","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.dmpk.2018.03.001_bib16","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/ndt\/gfh217","article-title":"A\u00a0simple vascular calcification score predicts cardiovascular risk in haemodialysis patients","volume":"19","author":"Adragao","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.dmpk.2018.03.001_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4155\/bio.10.8","article-title":"Early human ADME using microdoses and microtracers: bioanalytical considerations","volume":"2","author":"Dueker","year":"2010","journal-title":"Bioanalysis"},{"issue":"7","key":"10.1016\/j.dmpk.2018.03.001_bib18","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/js970486q","article-title":"Plasma-pooling methods to increase throughput for in\u00a0vivo pharmacokinetic screening","volume":"87","author":"Hop","year":"1998","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.dmpk.2018.03.001_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1124\/dmd.112.048603","article-title":"Metabolism and disposition of vilanterol, a long-acting beta(2)-adrenoceptor agonist for inhalation use in humans","volume":"41","author":"Harrell","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2018.03.001_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s13318-014-0182-0","article-title":"Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers","volume":"40","author":"Morris","year":"2015","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2018.03.001_bib21","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.2147\/DDDT.S107843","article-title":"Pharmacokinetics, absorption, and excretion of radiolabeled revexepride: a Phase I clinical trial using a microtracer and accelerator mass spectrometry-based approach","volume":"10","author":"Flach","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.dmpk.2018.03.001_bib22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.4155\/bio.09.188","article-title":"Accelerator mass spectrometry-enabled studies: current status and future prospects","volume":"2","author":"Arjomand","year":"2010","journal-title":"Bioanalysis"},{"issue":"1","key":"10.1016\/j.dmpk.2018.03.001_bib23","doi-asserted-by":"crossref","first-page":"FSO74","DOI":"10.4155\/fso.15.74","article-title":"Opportunities in low-level radiocarbon microtracing: applications and new technology","volume":"2","author":"Vuong","year":"2016","journal-title":"Future Sci OA"},{"issue":"13","key":"10.1016\/j.dmpk.2018.03.001_bib24","first-page":"3471","article-title":"Drug administration, international conference on harmonisation; guidance on M3(R2) nonclinical safety studies for the conduct of human clinical trials and Marketing authorization for Pharmaceuticals; availability","volume":"75","author":"Food and H.H.S","year":"2010","journal-title":"Notice Fed Regist"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436718300466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436718300466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:53:40Z","timestamp":1761162820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436718300466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1347436718300466"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2018.03.001","relation":{},"ISSN":["1347-4367"],"issn-type":[{"type":"print","value":"1347-4367"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I, open-label, single-dose micro tracer mass balance study of 14C-labeled ASP7991 in healthy Japanese male subjects using accelerator mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2018.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}